sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a Form 8.3 disclosure regarding its interests in Avadel Pharmaceuticals plc. Filed under the Irish Takeover Panel Act of 1997, the form details shareholdings exceeding 1% in the company. As of November 3, 2025, Vanguard's interests include ownership of 5,523,668 US$0.01 ordinary shares, equating to a 5.67% stake.
Additional transactions were recorded, with purchases of 5,582 shares and sales of 1,330 shares, all at $18.92 per share. No cash-settled derivative transactions or agreements related to options and derivatives were reported. There are also no indemnities or other agreements influencing securities actions.
This filing is part of regulatory compliance ensuring transparency in dealings with relevant securities during potential takeover situations.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.